Characteristics and Outcome of Patients with Early Complete Neurological Recovery after Thrombolysis for Acute Ischemic StrokeBlinzler C. · Breuer L. · Huttner H.B. · Schellinger P.D. · Schwab S. · Köhrmann M.
Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Recombinant tissue plasminogen activator (rt-PA) is the only approved specific therapy for acute ischemic stroke. This study analyzes demographic and clinical characteristics of patients with early complete neurological recovery after thrombolysis. Methods: Data of 320 consecutive patients treated with rt-PA within 3 h of stroke onset at our facility between April 2006 and March 2009 were extracted from our prospective institutional stroke and thrombolysis database. Baseline demographic parameters, risk factors, clinical characteristics as well as neuroradiologic findings of patients with complete recovery 24 h after treatment and at hospital discharge were analyzed. Outcome was evaluated using the modified Rankin Scale at 90 days. Results: Thirty patients (9.4%) were asymptomatic 24 h after thrombolysis and 70 (22%) at hospital discharge. Patients with complete recovery were younger, more often male, had milder stroke symptoms, less often cardioembolic strokes, fewer bleeding complications and more often normal follow-up imaging. In addition, in-hospital time was shorter and these patients retained a better functional outcome at 90 days. Only 1 patient who had completely recovered at hospital discharge died during the follow-up time. In multivariate regression analysis, only the National Institute of Health Stroke Score (NIHSS) on admission was predictive for complete recovery at both examined time points. Conclusion: Rapid complete recovery can be achieved in up to a fifth of acute stroke patients treated with thrombolysis. These patients are younger and have milder strokes, less often with cardioembolic origin. Better outcome and lower mortality are sustained at 3 months.
© 2010 S. Karger AG, Basel
- Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, Bone I: Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke 2002;33:2243–2246.
- Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, Erilä T, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Köhrmann M, Larrue V, Lees KR, Machnig T, Roine RO, Toni D, Vanhooren G; Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators: Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke 2008;39:3316–3322.
- Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, Levine SR; Multicentre tPA Stroke Survey Group: Predictors of good outcome after intravenous t-PA for acute ischemic stroke. Neurology 2001;57:474–480.
- Elkind MS, Prabharkaran S, Pittman J, Koroshetz W, Jacoby M, Johnston KC, GAIN Americas Investigators: Sex as a predictor of outcome in patients treated with thrombolysis for acute stroke. Neurology 2007;68:842–848.
- Delgado MG, Michel P, Naves M, Maeder P, Reichhart M, Wintermark M, Bogousslavsky J: Early profiles of clinical evolution after intravenous thrombolysis in an unselected stroke population. J Neurol Neurosurg Psychiatry 2010;81:282–285.
- Kent DM, Buchan AM, Hill MD: The gender effect in stroke thrombolysis: of CASES, controls, and treatment-effect modification. Neurology 2008;71:1080–1083.
- Kent DM, Price LL, Ringleb P, Hill MD, Selker HP: Sex-based difference in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke 2005;36:62–65.
- Saposnik G, Di Legge S, Webster F, Hachinski V: Predictors of major neurologic improvement after thrombolysis in acute stroke. Neurology 2005;65:1169–1174.
- Tandberg Askevold E, Naess H, Thomassen L: Predictors for recanalization after intravenous thrombolysis in acute ischemic stroke. J Stroke Cerebrovasc Dis 2007;16:21–24.
- Kimura K, Iguchi Y, Yamashita S, Shibazaki K, Kobayashi K, Inoue T: Atrial fibrillation as an independent predictor for no early recanalization after IV-t-PA in acute ischemic stroke. J Neurol Sci 2008;267:57–61.
- Saňák D, Herzig R, Král M, Bártková A, Zapletalová J, Hutyra M, Skoloudík D, Vlachová I, Veverka T, Horák D, Kaňovský P: Is atrial fibrillation associated with poor outcome after thrombolysis? J Neurol 2010;257:999–1003.
- Kimura K, Iguchi Y, Shibazaki K, Iwanaga T, Yamashita S, Aoki J: IV t-PA therapy in acute stroke patients with atrial fibrillation. J Neurol Sci 2009;276:6–8.
- Naess H, Idicula T, Lagallo N, Brogger J, Waje-Andreassen U, Thomassen L: Inverse relationship of baseline body temperature and outcome between ischemic stroke patients treated and not treated with thrombolysis: the Bergen stroke study. Acta Neurol Scand 2010;122:414–417.
- Uchino K, Massaro L, Hammer MD: Transient ischemic attack after tissue plasminogen activator: aborted stroke or unnecessary stroke therapy? Cerebrovasc Dis 2010;29:57–61.
- Winkler DT, Fluri F, Fuhr P, Wetzel SG, Lyrer PA, Ruegg S, Engelter ST. Thrombolysis in stroke mimics: frequency, clinical characteristics, and outcome. Stroke 2009;40:1522–1525.
- Brown DL, Johnston KC, Wagner DP, Haley EC Jr: Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke 2004;35:147–150.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.